Reviewing Eterna Therapeutics (NASDAQ:ERNA) and China Dongsheng International (OTCMKTS:CDSG)

Profitability

This table compares China Dongsheng International and Eterna Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
China Dongsheng International	N/A	N/A	N/A
Eterna Therapeutics	-7,513.88%	-1,466.71%	-117.48%

Insider & Institutional Ownership

70.6% of Eterna Therapeutics shares are held by institutional investors. 73.5% of China Dongsheng International shares are held by insiders. Comparatively, 4.5% of Eterna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares China Dongsheng International and Eterna Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Dongsheng International	N/A	N/A	-$100,000.00	N/A	N/A
Eterna Therapeutics	$70,000.00	73.19	-$21.67 million	($8.31)	-0.11

China Dongsheng International has higher earnings, but lower revenue than Eterna Therapeutics.

Risk and Volatility

China Dongsheng International has a beta of 15.42, meaning that its share price is 1,442% more volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 4.41, meaning that its share price is 341% more volatile than the S&P 500.

Summary

China Dongsheng International beats Eterna Therapeutics on 6 of the 8 factors compared between the two stocks.

About China Dongsheng International

China Dongsheng International, Inc. engages in the acquisition, exploration, and development of mineral properties. The company primarily explores for lithium. It holds an 80% interest in the Titan Projects located in Tanzania; and has right to earn 60% interest in the West End Lithium Project near Tonopah Nevada. China Dongsheng International, Inc. is based in Las Vegas, Nevada.

About Eterna Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.